Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics reported a net loss of $(2.19) million for the first quarter of 2026, significantly wider than the $(0.29) million loss in Q1 2025. The company also disclosed a negative working capital of approximately $(16.3) million and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern. Despite financial challenges, Oncotelic entered a strategic partnership with TechForce Robotics to commercialize an AI-enabled, GMP-compliant robotics platform and continues development of its immuno-oncology therapeutics through its GMP Bio joint venture.

Oncotelic Therapeutics' wholly owned subsidiary, Oncotelic Inc., completed a triangular merger on May 1, 2026, involving Neurobridge IP Holdings Incorporated and Lunai Bioworks, Inc. As part of the transaction, Oncotelic Inc. contributed its intellectual property assets to Neurobridge IP Holdings. In consideration for the merger, Lunai Bioworks issued 8 shares of Series B Convertible Preferred Stock with an aggregate stated value of $20,000,000, of which Oncotelic received 5 shares valued at $12,500,000. Oncotelic also secured a perpetual, royalty-free, exclusive license to use the assigned IP in all fields except Biodefense and Alzheimer's Disease.

Oncotelic Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, reporting a significant net income after tax of approximately $249.0 million. This marks a substantial improvement from a net loss of approximately $4.8 million in the prior fiscal year. The positive financial performance was primarily attributed to a non-cash increase in the estimated fair value of the company's investment in its joint venture, GMP Biotechnology Limited.

Oncotelic Therapeutics, Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company confirmed it has filed all reports required by the Securities Exchange Act of 1934 during the preceding 12 months. Oncotelic Therapeutics is designated as a non-accelerated filer and a smaller reporting company.